Your session is about to expire
← Back to Search
NK Cells + SCT for Leukemia
Study Summary
This trial is testing the safety and effectiveness of adding a natural killer cell treatment to the standard stem cell transplant for leukemia patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 30 Patients • NCT01877837Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on a daily dose of more than 10 mg of prednisone or similar steroids.My MDS is classified as intermediate or high-risk.My AML is considered high-risk or has specific mutations.I am not pregnant.I have Chronic Myeloid Leukemia that meets certain criteria.I have liver cirrhosis.My central nervous system was affected by my condition within the last 3 months.I do not have any infections that are not responding to treatment.I have not been diagnosed with any other cancer in the last 2 years.I have a blood cancer and meet the specific donor requirements.My vital organs are functioning well.My test shows high levels of specific antibodies or positive C1q.I am between 18 and 70 years old.I am HIV positive or have active hepatitis B or C.I am mostly active and can care for myself.
- Group 1: Mycophenolate mofetil
- Group 2: Tacrolimus
- Group 3: Total Body Irradiation One Dose
- Group 4: Cyclophosphamide
- Group 5: Mesna
- Group 6: Filgrastim
- Group 7: Melphalan
- Group 8: Fludarabine phosphate
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you speak to any other research that has been conducted involving Melphalan?
"Currently, 1120 clinical trials investigating the use of Melphalan are underway with 208 in Phase 3. While some studies take place in Hamburg and Hessen, a total of 32017 sites across the globe offer this medication trial to patients."
Does the research team accept participants below forty years old?
"This study requires participants that are between 18 and 70 years old. There are 1116 trials available for minors, while seniors have access to 4322 similar clinical studies."
Are there any open slots for individuals to join this clinical experiment?
"Per the information on clinicaltrials.gov, this medical trial is still accepting participants. It was published to their website on April 8th 2022 and has been updated as recently as November 17th of the same year."
Am I eligible to participate in this research program?
"This clinical trial seeks 24 individuals aged 18 to 70 with a diagnosis of leukemia, and meeting the following criteria: body weight greater than 42 kgs; an HLA-matched related or unrelated donor (A, B, C antigens and DRB1); presence of one or more high risk features such as a preceding MDS diagnosis or complex/monosomal karyotype."
What is the scope of participant involvement in this research endeavor?
"Correct. According to the details present on clinicaltrials.gov, this research is currently recruiting participants; since it was initially posted on April 8th 2022 and updated most recently November 17th 2022. A total of 24 patients need to be enrolled from a single location."
What ailment is Melphalan usually prescribed for?
"Melphalan is a commonly-prescribed treatment for atopic dermatitis. It can also be employed to address acute myelocytic leukemia, multiple sclerosis, and psoriasis."
Share this study with friends
Copy Link
Messenger